EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|September 1, 2002
'They don't want to treat children'
It's 10:45 p.m. on a Sunday. You're winding down from an enjoyable weekend when, suddenly, the sound of your pager summons you. There's a call from your local hospital.
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
2
EADV 2026 Day 1: Late-Breaking Data, Emerging Therapies, and New Directions in Dermatology
3
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
4
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
5